Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

University of Wisconsin–Madison

ClinicalTrials.gov lists University of Wisconsin–Madison as lead sponsor of 1,182 trials. It has 323 active development programs and 248 approved assets.

US Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

89 0 1990 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 89 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 68 in 2026 and about 68 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 89 already registered with a 2026 start date: at the cutoff, 38 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 5 trials are registered to start in 2027 or later.

Logo University of Wisconsin-Madison, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers University of Wisconsin–Madison: 1,182 lead-sponsored trials and 1 legal-entity registration. The parent company on record for University of Wisconsin–Madison is University of Wisconsin System, which does not have its own page on this site.

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the University of Wisconsin–Madison report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (518)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Trials by start year as sponsor or collaborator (34)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 89
2025 65
2024 85
2023 83
2022 66
2021 64
2020 55
2019 79
2018 56
2017 68

Prediction, not a registry value: median of 36 months from start to primary completion across 103 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 899 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (323)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Letermovir Cytomegalovirus Infections Phase 3 1
Buprenorphine + naloxone (Suboxone) Opioid-Related Disorders Phase 3 1
Epidural Analgesia Intraoperative Complications Phase 3 1
Epidural Analgesia Pain Phase 3 1
Buprenorphine + naloxone (Suboxone) Substance-Related Disorders Phase 3 1

Approved assets (248)

Shown in this order: max phase first.

Approved assets
Drug Trials
Nicotine Patch 14
INFLUENZA VACCINE 9
Calcium/Vitamin D 7
Varenicline 7
(nab)-paclitaxel 4

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
36% hit target (n=499) 44% on time (n=470)

Biomarker capability evidence (1,198)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABCD1 Trial sponsor Named in trial inclusion criteria
ABL1 Trial sponsor Named in trial inclusion criteria
ABO Trial sponsor Named in trial inclusion criteria
ACAT1 Trial sponsor Named in trial inclusion criteria
ACD Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.

Counted at group level under University of Wisconsin System: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.